In The News Posted January 31, 2019 Share Posted January 31, 2019 SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), today provided an update on the U.S. commercial relaunch of Probuphine (buprenorphine) implant, its unique six-month treatment for Opioid Use Disorder (OUD). Titan has successfully... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.